An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects.
| Publicado en: | Alzheimer Disease & Associated Disorders Vol. 39; no. 3; pp. 151 - 158 |
|---|---|
| Autores principales: | , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Lippincott Williams & Wilkins
Jul-Sep2025
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=187430366&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 187430366 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 08930341 MZB jtl: Alzheimer Disease & Associated Disorders issn: 08930341 maglogo: N pubinfo: dt: Jul-Sep2025 vid: 39 iid: 3 pid: 433 pub: Lippincott Williams & Wilkins place: Baltimore, Maryland artinfo: ui: 187430366 10.1097/WAD.0000000000000680 187430366 ppf: 151 ppct: 7 formats: tig: atl: An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects. aug: au: Rawal, Sumit Wildsmith, Kristin R. Aluri, Jagadeesh Yagi, Takuya Chang, Min-Kun Niu, Hongmei Zhou, Jin Horie, Kanta Takahashi, Eri Boyd, Peter Reyderman, Larisa affil: Eisai Inc., Nutley, NJ sug: pubtype: Academic Journal doctype: Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|